…I’m amazed you’re still (sorta) upbeat about the prospects of...

First 1799 Last

Share
Profile

Follow
georgeaux

10,851 Posts.

504

14/09/23

19:55

Post #: 69863887
Share

Originally posted by zebster ↑

G, Have you tried Googling it? The answer was the 4th hit on my browser.

Re- the cost saving initiatives: Dunno for sure, but I'd be lying if I said it didn't also get my attention. I'm hoping it simply relates to having a good hard look at differentiating the 'nice to do' spending from the 'absolutely need to do' spending and culling the former while retaining the latter. An efficiency drive, if you will.
I think adverse speculation around this aspect, along with the duster for Target #5, were prolly the two things that drove the market today. Otherwise, it read to me as a pretty routine (now bi-monthly?) update.
I think the market, with it's frayed nerves, for POS and other Ni juniors more generally (hello PAN and, drawing somewhat of a long comparative bow, CHN) is in no mood for goodwill or giving the benefit of the doubt atm. Sell first, ask questions later kinda stuff. That's understandable for pips traders with a ST horizon or nervous retails who have had enough or are easily spooked. I'm in neither of those camps but face the operational (investing) challenge of filling up when a) the price is right (for me) and b) the available depth is there. That was last month for me. Congats to anyone else who is building or has built any meaningful stake AND who managed to wait until now to do so. That said, one never knows when the train will leave the station. I'd like a buck (mate) for every time I've held out to eek out that last pip or two of value for a LT entry, only to be left smarting on the platform.
The weekly suggests a ST capitulation low may not be far away, if not seen already (today?). The joys of interpreting The Business End (RH edge) of the chart vs. when time has marched on and today's action sits in the middle of the screen.

PS. Ok, G, I'll throw you a bone: Ba11$ To The Wall.

Expand

…I’m amazed you’re still (sorta) upbeat about the prospects of this company (and you’re investment) going forward ?!

…btw, I did end up Googling it and it came up with that result but it didn’t look right in the context of your post…but hey, I’ll take it as a win…

POS Price at posting: 1.8¢ Sentiment: None Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

There are more pages in this discussion • 678 more messages in this thread...

First 1799 Last

Add POS (ASX) to my watchlist

(20min delay)
Last 0.4¢		Change 0.000(0.00%)		Mkt cap ! $16.81M

Open	High	Low	Value	Volume
0.3¢	0.4¢	0.3¢	$12.05K	3.098M

Buyers (Bids)

No.	Vol.	Price($)
113	92178699	0.3¢

Sellers (Offers)

Price($)	Vol.	No.
0.4¢	50268487	53

View Market Depth

No.	Vol.	Price($)
113	92178699	0.003
39	67152490	0.002
18	35412754	0.001
0	0	0.000
0	0	0.000

Price($)	Vol.	No.
0.004	50268487	53
0.005	28970868	19
0.006	8516341	10
0.007	1668099	8
0.008	1800000	1

Last trade - 16.10pm 07/10/2024 (20 minute delay)

POS (ASX) Chart

…I’m amazed you’re still (sorta) upbeat about the prospects of...

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

…I’m amazed you’re still (sorta) upbeat about the prospects of...

Top Stories

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News